Ignite Creation Date:
2024-05-06 @ 8:24 PM
Last Modification Date:
2024-10-26 @ 3:26 PM
Study NCT ID:
NCT06367153
Status:
COMPLETED
Last Update Posted:
2024-06-27
First Post:
2024-04-11
Brief Title:
A Study in Healthy Men and Women to Test Whether BI 1569912 Influences the Amount of Repaglinide Midazolam and Bupropion in the Blood
Sponsor:
Boehringer Ingelheim
Organization:
Boehringer Ingelheim
Study Overview
Official Title:
The Effect of Multiple Doses of BI 1569912 on the Single-dose Pharmacokinetics of Repaglinide Midazolam and Bupropion Following Oral Administration in Healthy Male and Female Subjects an Open-label 2-period Fixed-sequence Trial
Status:
COMPLETED
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The main objective of this trial is to investigate the effect of multiple oral doses of BI 1569912 on the pharmacokinetics of a single oral dose of repaglinide midazolam and bupropion ie sensitive CYP2C8 CYP3A4 and CYP2B6 substrates
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2023-510461-10-00 | REGISTRY | None | None |
| U1111-1303-9187 | REGISTRY | WHO International Clinical Trials Registry Platform ICTRP | None |